Explore

Trendline Trendline
Nuvation Bio's Brain Cancer Drug Shows Promise, Boosting Stock

Nuvation Bio's Brain Cancer Drug Shows Promise, Boosting Stock

Nuvation Bio's Brain Cancer Drug Shows Promise, Boosting Stock
Trendline Trendline
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results for Investors

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results for Investors

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results for Investors
Trendline Trendline
Zacks Investment Research Adds Three Stocks to Strong Sell List Amid Earnings Revisions

Zacks Investment Research Adds Three Stocks to Strong Sell List Amid Earnings Revisions

Zacks Investment Research Adds Three Stocks to Strong Sell List Amid Earnings Revisions
Reuters Reuters
Novartis backs full year forecast after $6 billion profit beat helped by one-offs

Novartis backs full year forecast after $6 billion profit beat helped by one-offs

By Bhanvi Satija and Marleen Kaesebier LONDON, July 21 - Novartis beat second-quarter profit forecasts and kept its 2026 outlook unchanged on Tuesday, saying one-off benefits that helped the quarter would reverse as it increases research and launch spending in the second half.
Trendline Trendline
Arrowhead Pharmaceuticals Reports Positive Phase 3 Data for Triglyceride-Lowering Drug, Challenging Ionis

Arrowhead Pharmaceuticals Reports Positive Phase 3 Data for Triglyceride-Lowering Drug, Challenging Ionis

Arrowhead Pharmaceuticals Reports Positive Phase 3 Data for Triglyceride-Lowering Drug, Challenging Ionis
Trendline Trendline
AstraZeneca Faces Challenges in Reaching $80 Billion Sales Target After Wainua Setback

AstraZeneca Faces Challenges in Reaching $80 Billion Sales Target After Wainua Setback

AstraZeneca Faces Challenges in Reaching $80 Billion Sales Target After Wainua Setback
Trendline Trendline
Biotech IPOs Outperform AI Listings with 55% Return

Biotech IPOs Outperform AI Listings with 55% Return

Biotech IPOs Outperform AI Listings with 55% Return
Trendline Trendline
Altesa BioSciences Appoints Brett Haumann as CEO Amidst Strategic Growth Phase

Altesa BioSciences Appoints Brett Haumann as CEO Amidst Strategic Growth Phase

Altesa BioSciences Appoints Brett Haumann as CEO Amidst Strategic Growth Phase
TheStreet TheStreet
Analyst sends chilling Oracle stock verdict

Analyst sends chilling Oracle stock verdict

CLSA started coverage of Oracle (ORCL) with a Hold rating and a $145 price target, which is among Wall Street's lowest.  The call lands while Oracle sits near a 52-week low, down roughly 62% from its September peak. The rating itself is not the scary part, as a Hold rating is neutral by ...
Trendline Trendline
Altesa BioSciences Appoints Brett Haumann as CEO Amidst Strategic Growth Initiatives

Altesa BioSciences Appoints Brett Haumann as CEO Amidst Strategic Growth Initiatives

Altesa BioSciences Appoints Brett Haumann as CEO Amidst Strategic Growth Initiatives
Trendline Trendline
Analysts Recommend Holding AI Hardware Stocks Amid Market Volatility

Analysts Recommend Holding AI Hardware Stocks Amid Market Volatility

Analysts Recommend Holding AI Hardware Stocks Amid Market Volatility
Trendline Trendline
Stevanato Group to Announce Second Quarter 2026 Financial Results and Host Webcast

Stevanato Group to Announce Second Quarter 2026 Financial Results and Host Webcast

Stevanato Group to Announce Second Quarter 2026 Financial Results and Host Webcast